Once-weekly bortezomib had similar effectiveness and lower thrombocytopenia occurrence compared with twice-weekly bortezomib regimen in treating patients with newly diagnosed multiple myeloma in China

The study aims to examine the treatment effect and adverse reactions of patients with newly diagnosed MM receiving different bortezomib-based regimens. This was a retrospective study of patients with newly diagnosed MM and who were treated with bortezomib-based combined chemotherapy at the Departmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Rongxin, Hu, Xudong, Zhou, Shuping, Zhang, Qianying, Huang, He, Sun, Ni, Guo, Wenjian, Yu, Kang, Lin, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
4800
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775427/
https://www.ncbi.nlm.nih.gov/pubmed/31574817
http://dx.doi.org/10.1097/MD.0000000000017147

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775427/
https://www.ncbi.nlm.nih.gov/pubmed/31574817
http://dx.doi.org/10.1097/MD.0000000000017147

Ejemplares similares